Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 12/20 | 0.58 |
| ▸ | TYK2 | P29597 | 4/20 | 0.58 |
| ▸ | JAK2 | O60674 | 10/20 | 0.58 |
| ▸ | JAK3 | P52333 | 2/20 | 0.54 |
| ▸ | IKBKB | O14920 | 1/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10063385 | 0.90 | JAK1 (0.73) | JAK1TYK2JAK2JAK3 | |
| SCHEMBL45132 | 0.90 | TYK2 (0.61) | JAK1TYK2JAK2JAK3 | |
| SCHEMBL13031180 | 0.85 | JAK1 (0.68) | JAK1TYK2JAK2JAK3IKBKB | |
| SCHEMBL13031243 | 0.84 | JAK1 (0.80) | JAK1TYK2JAK2JAK3IKBKB | |
| SCHEMBL42533 | 0.84 | JAK1 (0.73) | JAK1TYK2JAK2JAK3IKBKB | |
| SCHEMBL42851 | 0.82 | JAK2 (0.64) | JAK1TYK2JAK2JAK3IKBKB | |
| SCHEMBL45183 | 0.82 | JAK1 (0.59) | JAK1TYK2JAK2JAK3IKBKB | |
| SCHEMBL41136 | 0.82 | JAK2 (0.72) | JAK1TYK2JAK2JAK3IKBKB | |
| SCHEMBL13031259 | 0.82 | JAK1 (0.72) | JAK1TYK2JAK2JAK3IKBKB | |
| SCHEMBL29469350 | 0.81 | JAK1 (0.56) | JAK1TYK2JAK2JAK3IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143915-A1 | TRIAZOLOPYRIDINES AS TYK2 INHIBITORS | CELLZOME LIMITED (GB) | 2013-06-06 | — | — | US | claimed |
| EP-2588105-A1 | TRIAZOLOPYRIDINES AS TYK2 INHIBITORS | Cellzome Limited (GB) | 2013-05-08 | — | — | EP | claimed |
| WO-2012000970-A1 | TRIAZOLOPYRIDINES AS TYK2 INHIBITORS | CELLZOME LIMITED (GB) | 2012-01-05 | — | — | WO | claimed |
| US-20130143915-A1 | TRIAZOLOPYRIDINES AS TYK2 INHIBITORS | CELLZOME LIMITED (GB) | 2013-06-06 | — | — | US | disclosed |
| US-20130143915-A1 | TRIAZOLOPYRIDINES AS TYK2 INHIBITORS | CELLZOME LIMITED (GB) | 2013-06-06 | — | — | US | disclosed |
| US-20130143915-A1 | TRIAZOLOPYRIDINES AS TYK2 INHIBITORS | CELLZOME LIMITED (GB) | 2013-06-06 | — | — | US | disclosed |
| EP-2588105-A1 | TRIAZOLOPYRIDINES AS TYK2 INHIBITORS | Cellzome Limited (GB) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012000970-A1 | TRIAZOLOPYRIDINES AS TYK2 INHIBITORS | CELLZOME LIMITED (GB) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143915-A1 | TRIAZOLOPYRIDINES AS TYK2 INHIBITORS | TYK2, IRAK1, IRAK2 | JAK1 6/4885TYK2 1/4885JAK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.